<p>Sutro Biopharma, Inc.（纳斯达克代码：STRO - 获取免费报告）在 12 月份经历了大幅下降的空头头寸。截至 12 月 15 日，空头头寸总计为 560,264 股，比 11 月 30 日的 3,977,435 股下降了 85.9%。根据平均每日交易量 139,822 股，目前的覆盖天数比率为 4.0 天。公司约有 7.0% 的股份被做空。根据平均每日交易量 139,822 股，目前的覆盖天数比率为 4.0 天。</p>
<p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
<h2>Sutro Biopharma 价格表现</h2>
<p>周三，STRO 的股价上涨 0.25 美元，达到 10.63 美元。该公司的股票交易量为 40,237 股，而其平均交易量为 116,353 股。该公司的 50 日移动平均价格为 9.48 美元，200 日移动平均价格为 8.79 美元。Sutro Biopharma 的 52 周低点为 5.23 美元，52 周高点为 21.50 美元。该公司的市值为 9042 万美元，市盈率为-0.41，贝塔值为 1.61。</p>
<p>Sutro Biopharma（纳斯达克代码：STRO - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为-0.67 美元，低于市场共识预期的-0.42 美元，差距为 0.25 美元。该季度的营业收入为 969 万美元，而市场共识预期为 1014 万美元。Sutro Biopharma 的净利润率为-206.77%，股本回报率为-852.70%。分析师平均预测 Sutro Biopharma 在本年度将发布-2.92 的每股收益。</p>
<h2>Sutro Biopharma 内部交易</h2>
<p>在其他新闻中，董事 Connie Matsui 在 10 月 15 日（星期三）购买了 5000 股公司的股票，交易价格为每股 8.00 美元，总交易额为 40,000 美元。收购后，该董事直接持有 5000 股公司股票，价值 40,000 美元。此次交易使其持股增加了∞。该购买在向 SEC 的法律文件中披露，相关文件可通过 SEC 网站访问。在上个季度，内部人士共购买了 11,175 股公司股票，价值 89,598 美元。公司内部人士持有公司 5.90% 的股份。</p>
<h2>对 Sutro Biopharma 的对冲基金看法</h2>
<p>一些机构投资者最近调整了对 STRO 的持股。Catalyst Funds Management Pty Ltd 在第二季度新购入了 Sutro Biopharma 的股份，价值约 27,000 美元。Savant Capital LLC 在第二季度新购入了 Sutro Biopharma 的股份，价值约 37,000 美元。Bridgeway Capital Management LLC 在第三季度将其在 Sutro Biopharma 的持股增加了 232.6%。Bridgeway Capital Management LLC 现在拥有 42,900 股公司股票，价值 37,000 美元，此前在此期间又购买了 30,000 股。CWM LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 73.2%。CWM LLC 现在拥有 56,657 股公司股票，价值 40,000 美元，此前在此期间又购买了 23,941 股。最后，Vanguard Personalized Indexing Management LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 174.8%。Vanguard Personalized Indexing Management LLC 现在拥有 60,617 股公司股票，价值 43,000 美元，此前在上个季度又购入了 38,561 股。96.99% 的股票由机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>一些股票分析师最近对 STRO 股票发布了报告。Weiss Ratings 在周一的研究报告中重申了对 Sutro Biopharma 的 “卖出（d-）” 评级。Wedbush 在 12 月 2 日（星期二）的研究报告中重申了 “中性” 评级，并将 Sutro Biopharma 的目标价上调至 100.00 美元（从 20.00 美元上调）。德意志银行在 12 月 17 日（星期三）的研究报告中重申了对 Sutro Biopharma 的 “买入” 评级。华尔街 Zen 在 11 月 8 日（星期六）的研究报告中将 Sutro Biopharma 的评级从 “持有” 下调至 “卖出”。最后，HC Wainwright 在周一的研究报告中将 Sutro Biopharma 的目标价提高至 10.00 美元，并给予该股票 “中性” 评级。两位分析师对该股票给予了买入评级，四位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 33.60 美元。</p>
<p><strong>获取我们关于 STRO 的最新报告</strong></p>
<h2>Sutro Biopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化蛋白治疗药物，这在传统的基于细胞的表达系统中可能无法实现。</p>
<p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同预临床和临床开发阶段的免疫肿瘤候选药物管线。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Sutro Biopharma 更好</li>
<li>100 万美元在退休后能维持多久？</li>
<li>这个假期你花的每一美元都是最好的</li>
<li>华盛顿为战争做准备</li>
<li>黄金警报</li>
<li>将这些代码输入到你的普通经纪账户中</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。有关此故事的任何问题或评论，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
<p>在考虑 Sutro Biopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sutro Biopharma 并不在名单上。</p>
<p>虽然 Sutro Biopharma 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

STRO

<p>Sutro Biopharma, Inc. (NASDAQ:STRO) 在 12 月份的空头头寸下降了 85.9%，截至 12 月 15 日，股票总数为 560,264 股。基于平均每日交易量 139,822 股，空头头寸比率为 4.0 天。股价上涨了 0.25 美元，达到 10.63 美元，交易量为 40,237 股。分析师的评级不一，有些分析师上调评级，而另一些则下调评级</p>

<p>Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 560,264 shares, a drop of 85.9% from the November 30th total of 3,977,435 shares. Based on an average daily trading volume, of 139,822 shares, the days-to-cover ratio is presently 4.0 days. Approximately 7.0% of the shares of the company are sold short. Approximately 7.0% of the shares of the company are sold short. Based on an average daily trading volume, of 139,822 shares, the days-to-cover ratio is presently 4.0 days.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc.（纳斯达克代码：STRO - 获取免费报告）在 12 月份经历了大幅下降的空头头寸。截至 12 月 15 日，空头头寸总计为 560,264 股，比 11 月 30 日的 3,977,435 股下降了 85.9%。根据平均每日交易量 139,822 股，目前的覆盖天数比率为 4.0 天。公司约有 7.0% 的股份被做空。根据平均每日交易量 139,822 股，目前的覆盖天数比率为 4.0 天。</p>
</div><p>Get <strong>Sutro Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
</div><h2>Sutro Biopharma Price Performance</h2>
<div class="lb-trans"><h2>Sutro Biopharma 价格表现</h2>
</div><p>Shares of STRO traded up $0.25 on Wednesday, hitting $10.63. The company's stock had a trading volume of 40,237 shares, compared to its average volume of 116,353. The company has a 50 day moving average price of $9.48 and a 200 day moving average price of $8.79. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $21.50. The company has a market capitalization of $90.42 million, a PE ratio of -0.41 and a beta of 1.61.</p>
<div class="lb-trans"><p>周三，STRO 的股价上涨 0.25 美元，达到 10.63 美元。该公司的股票交易量为 40,237 股，而其平均交易量为 116,353 股。该公司的 50 日移动平均价格为 9.48 美元，200 日移动平均价格为 8.79 美元。Sutro Biopharma 的 52 周低点为 5.23 美元，52 周高点为 21.50 美元。该公司的市值为 9042 万美元，市盈率为-0.41，贝塔值为 1.61。</p>
</div><p>Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.25). The business had revenue of $9.69 million during the quarter, compared to the consensus estimate of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. On average, equities analysts forecast that Sutro Biopharma will post -2.92 EPS for the current year.</p>
<div class="lb-trans"><p>Sutro Biopharma（纳斯达克代码：STRO - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为-0.67 美元，低于市场共识预期的-0.42 美元，差距为 0.25 美元。该季度的营业收入为 969 万美元，而市场共识预期为 1014 万美元。Sutro Biopharma 的净利润率为-206.77%，股本回报率为-852.70%。分析师平均预测 Sutro Biopharma 在本年度将发布-2.92 的每股收益。</p>
</div><h2>Insider Transactions at Sutro Biopharma</h2>
<div class="lb-trans"><h2>Sutro Biopharma 内部交易</h2>
</div><p>In other news, Director Connie Matsui bought 5,000 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director directly owned 5,000 shares of the company's stock, valued at $40,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 11,175 shares of company stock valued at $89,598. Company insiders own 5.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Connie Matsui 在 10 月 15 日（星期三）购买了 5000 股公司的股票，交易价格为每股 8.00 美元，总交易额为 40,000 美元。收购后，该董事直接持有 5000 股公司股票，价值 40,000 美元。此次交易使其持股增加了∞。该购买在向 SEC 的法律文件中披露，相关文件可通过 SEC 网站访问。在上个季度，内部人士共购买了 11,175 股公司股票，价值 89,598 美元。公司内部人士持有公司 5.90% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Sutro Biopharma</h2>
<div class="lb-trans"><h2>对 Sutro Biopharma 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of STRO. Catalyst Funds Management Pty Ltd acquired a new position in shares of Sutro Biopharma during the second quarter worth approximately $27,000. Savant Capital LLC bought a new stake in shares of Sutro Biopharma during the second quarter worth approximately $37,000. Bridgeway Capital Management LLC lifted its holdings in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock valued at $37,000 after buying an additional 30,000 shares during the period. CWM LLC lifted its holdings in Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company's stock valued at $40,000 after buying an additional 23,941 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Sutro Biopharma by 174.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company's stock valued at $43,000 after acquiring an additional 38,561 shares during the last quarter. 96.99% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 STRO 的持股。Catalyst Funds Management Pty Ltd 在第二季度新购入了 Sutro Biopharma 的股份，价值约 27,000 美元。Savant Capital LLC 在第二季度新购入了 Sutro Biopharma 的股份，价值约 37,000 美元。Bridgeway Capital Management LLC 在第三季度将其在 Sutro Biopharma 的持股增加了 232.6%。Bridgeway Capital Management LLC 现在拥有 42,900 股公司股票，价值 37,000 美元，此前在此期间又购买了 30,000 股。CWM LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 73.2%。CWM LLC 现在拥有 56,657 股公司股票，价值 40,000 美元，此前在此期间又购买了 23,941 股。最后，Vanguard Personalized Indexing Management LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 174.8%。Vanguard Personalized Indexing Management LLC 现在拥有 60,617 股公司股票，价值 43,000 美元，此前在上个季度又购入了 38,561 股。96.99% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of equities analysts recently issued reports on STRO shares. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Sutro Biopharma in a research report on Monday. Wedbush restated a &#34;neutral&#34; rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;buy&#34; rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Sutro Biopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Finally, HC Wainwright lifted their target price on Sutro Biopharma to $10.00 and gave the stock a &#34;neutral&#34; rating in a research report on Monday. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $33.60.</p>
<div class="lb-trans"><p>一些股票分析师最近对 STRO 股票发布了报告。Weiss Ratings 在周一的研究报告中重申了对 Sutro Biopharma 的 “卖出（d-）” 评级。Wedbush 在 12 月 2 日（星期二）的研究报告中重申了 “中性” 评级，并将 Sutro Biopharma 的目标价上调至 100.00 美元（从 20.00 美元上调）。德意志银行在 12 月 17 日（星期三）的研究报告中重申了对 Sutro Biopharma 的 “买入” 评级。华尔街 Zen 在 11 月 8 日（星期六）的研究报告中将 Sutro Biopharma 的评级从 “持有” 下调至 “卖出”。最后，HC Wainwright 在周一的研究报告中将 Sutro Biopharma 的目标价提高至 10.00 美元，并给予该股票 “中性” 评级。两位分析师对该股票给予了买入评级，四位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 33.60 美元。</p>
</div><p><strong>Get Our Latest Report on STRO</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 STRO 的最新报告</strong></p>
</div><h2>Sutro Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Sutro Biopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化蛋白治疗药物，这在传统的基于细胞的表达系统中可能无法实现。</p>
</div><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同预临床和临床开发阶段的免疫肿瘤候选药物管线。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Sutro Biopharma</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Washington prepares for war</li>
<li>GOLD ALERT</li>
<li>Punch these codes into your ordinary brokerage account</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Sutro Biopharma 更好</li>
<li>100 万美元在退休后能维持多久？</li>
<li>这个假期你花的每一美元都是最好的</li>
<li>华盛顿为战争做准备</li>
<li>黄金警报</li>
<li>将这些代码输入到你的普通经纪账户中</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。有关此故事的任何问题或评论，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
</div><p>Before you consider Sutro Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sutro Biopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sutro Biopharma 并不在名单上。</p>
</div><p>While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sutro Biopharma 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sutro Biopharma, Inc.（纳斯达克股票代码：STRO）在 12 月份的空头头寸减少了 85.9%